Etesian Wealth Advisors Inc. Sells 2,860 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Etesian Wealth Advisors Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,708 shares of the biopharmaceutical company's stock after selling 2,860 shares during the period. Etesian Wealth Advisors Inc.'s holdings in Gilead Sciences were worth $1,174,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. HHM Wealth Advisors LLC boosted its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares during the period. nVerses Capital LLC bought a new position in shares of Gilead Sciences during the third quarter valued at about $25,000. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $29,000. Finally, Valued Wealth Advisors LLC increased its holdings in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 161 shares during the period. 83.67% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the company's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 572,824 shares of company stock worth $53,611,715. Company insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Oppenheimer lifted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. Royal Bank of Canada reissued a "sector perform" rating and set a $84.00 price objective on shares of Gilead Sciences in a research report on Monday, February 3rd. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Morgan Stanley raised shares of Gilead Sciences from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $87.00 to $113.00 in a research note on Friday, January 10th. Finally, JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $98.39.

Gilead Sciences Stock Performance

Shares of GILD stock traded down $2.00 on Friday, reaching $96.04. The stock had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51. The stock has a market cap of $119.69 billion, a P/E ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The company has a 50 day simple moving average of $93.04 and a 200 day simple moving average of $86.76.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.29 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.